Table 2. Baseline characteristics for patients included in analysis.
| Variable | Control (n = 636) | Intervention (n = 591) | p-value |
| N (%) | N (%) | ||
| PCT 1 | 164 (25.8%) | 166 (28.1%) | 0.399 |
| PCT 2 | 339 (53.3%) | 237 (40.1%) | <0.001 |
| PCT 3 | 133 (20.9%) | 152 (25.7%) | 0.054 |
| Male | 370 (58.2%) | 347 (58.7%) | 0.894 |
| Smoking | 77 (12.1%) | 66 (11.2%) | 0.672 |
| Comorbidity | |||
| Hypertension | 341 (53.6%) | 335 (56.7%) | 0.307 |
| IHD | 115 (14.9%) | 95 (16.1%) | 0.392 |
| CVD | 22 (3.46%) | 15 (2.54%) | 0.438 |
| Heart failure | 15 (2.36%) | 17 (2.88%) | 0.697 |
| PVD | 7 (1.10%) | 9 (1.52%) | 0.690 |
| Renal failure | 13 (2.04%) | 12 (2.03%) | 1.000 |
| Ethnicity | |||
| White | 365 (57.4%) | 271 (45.9%) | <0.001 |
| Asian | 98 (15.4%) | 202 (34.2%) | <0.001 |
| Black | 20 (3.14%) | 33 (5.58%) | 0.050 |
| Other | 20 (3.14%) | 22 (3.72%) | 0.690 |
| Baseline assessment of outcome measures | |||
| Primary outcome (combined control) | 61 (9.59%) | 76 (12.9%) | 0.084 |
| Controlled HbA1c (< = 7.0%/53 mmol/mol) | 347 (54.6%) | 326 (55.2%) | 0.878 |
| Controlled blood pressure (<140/80 mmHg) | 354 (55.7%) | 324 (54.8%) | 0.812 |
| Controlled cholesterol (<154 mg/dl/4 mmol/l) | 305 (48.0%) | 308 (52.1%) | 0.162 |
| Individual factors (mean/sd) | |||
| HbA1c | 7.22 (1.24) | 7.18 (1.23) | 0.470 |
| Systolic BP | 137.5 (17.3) | 137.0 (18.0) | 0.528 |
| Diastolic BP | 80.6 (10.0) | 79.3 (10.7) | 0.005 |
| Total Cholesterol | 4.05 (1.04) | 3.99 (1.18) | 0.231 |